Evgen Pharma PLC Series B Fund Raise by partner, Stalicla SA
16 Janeiro 2024 - 12:07PM
RNS Non-Regulatory
TIDMEVG
Evgen Pharma PLC
16 January 2024
Evgen Pharma plc
("Evgen" or "the Company" or "the Group")
Evgen Notes First Closing of Series B Fund Raise by Partner,
Stalicla SA
Alderley Park, UK - 16 January 2024: Evgen Pharma plc (AIM: EVG,
Evgen), a clinical stage drug development company developing
sulforaphane-based medicines, notes that Stalicla SA, its partner
in autism spectrum disorder (ASD) and other neurodevelopmental
disorders has announced that it has raised $17.4m inclusive of a
credit facility to support programmes on STP1 their first asset in
Autism Spectrum Disorder (ASD) and a further asset in Substance Use
Disorders (SUD) together with a biosampling and patient
identification study in ASD.
Evgen continues to work with Stalicla on delivery of a milestone
payment for SFX-01 (Stalicla's STP2). The companies are engaged in
analysis and interpretation of Evgen's recent Phase 1b healthy
volunteer PK/PD study and the implications for a future Phase 2
trial in ASD. The Company will provide updates on the status of the
programme in due course and has not anticipated any milestone
payments from Stalicla in its financial forecasting.
Dr Huw Jones, Evgen CEO commented:
"We extend our congratulations to Stalicla on this round of
financing and look forward to continuing discussions on SFX-01 in
ASD. In the meantime we continue to advance our internal programme
in glioblastoma with the Erasmus medical centre in Rotterdam, NL
and our pre-clinical programmes in rhabdomyosarcoma, glioblastoma,
bowel cancer and breast cancer with our leading academic
collaborators."
-Ends-
Enquiries:
Evgen Pharma plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO +44 1625 466591
Cavendish (Nominated Advisor
and Broker)
Geoff Nash / Teddy Whiley (Corporate
Finance)
Nigel Birks (ECM) +44 20 7220 0500
Instinctif Partners +44 207 457 2020
Melanie Toyne-Sewell / Jack Kincade evgen@instinctif.com
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the highly biologically
active compound sulforaphane and novel proprietary analogues based
on sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of
synthetic sulforaphane and alpha-cyclodextrin and has undergone
clinical trials for oestrogen-positive (ER+) metastatic breast
cancer and recently a Phase 1b study of the Company's new enteric
coated tablet formulation. The FDA has granted Orphan Drug status
to SFX-01 in malignant glioma. SFX-01 will be investigated
initially in this indication as an investigator sponsored study in
the Netherlands supported by a substantial non-dilutive grant.
The Company also has a wide number of collaborations with
leading academic centres in the UK, Europe and the US as part of
the continuing strategy to build the scientific data for the
compound. Recently, Evgen completed an out-licensing transaction
with Stalicla SA, a Swiss specialist company in neurodevelopmental
disorders, commencing with autism spectrum disorder. The deal, if
successful, will generate milestone payments of $160.5m and a
double-digit royalty on sales.
The Company has its headquarters and registered office at
Alderley Park, Cheshire. It is listed on AIM in London and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com .
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEASFKFESLEFA
(END) Dow Jones Newswires
January 16, 2024 10:07 ET (15:07 GMT)
Evgen Pharma (LSE:EVG)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Evgen Pharma (LSE:EVG)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024